News Updates
Scope

Tue, May 26, 2026

1 updates
CLYM
7:00 AM

Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026

WELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced upcoming presentations for its CLYM116 and budoprutug programs at the European Renal

Presentation / Abstract • Phase 1Focused Oral presentation Fri, Jun 5, 2026, 3:03 PM BSTclimbbio.com

Thu, May 14, 2026

1 updates
CLYM
7:00 AM

Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress

WELLESLEY HILLS, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced an upcoming presentation on its budoprutug program at the European Hematology

Presentation / Abstract • Phase 1Poster presentation Sat, Jun 13, 2026, 6:45 PM CESTclimbbio.com

Tue, May 12, 2026

1 updates
CLYM
7:00 AM

Climb Bio to Present at Upcoming Investor Conferences

WELLESLEY HILLS, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences

climbbio.com

Thu, May 7, 2026

1 updates

Tue, May 5, 2026

1 updates
CLYM
7:00 AM

Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts

Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; Fast Track Designation received for pMN Initial data from ITP trial anticipated in June; initial data

Trial Results • Phase 1climbbio.com

Tue, Apr 28, 2026

1 updates
CLYM
7:00 AM

Climb Bio, Inc. Announces $110.0 Million Private Placement

WELLESLEY HILLS, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional

climbbio.com

Wed, Apr 8, 2026

1 updates

Tue, Apr 7, 2026

1 updates

Thu, Mar 5, 2026

1 updates